Does High Cerebral Microbleed Burden Increase the Risk of Intracerebral Hemorrhage After Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke?

Karissa N. Arca, Bart M Demaerschalk, Diana Almader-Douglas, Dean Marko Wingerchuk, Cumara B. O'Carroll

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The risk of developing intracerebral hemorrhage (ICH) after the administration of intravenous tissue plasminogen activator for acute ischemic stroke is well established in the general population. However, the risk associated with stroke thrombolysis in patients with a history of cerebral microbleeds (CMBs) is undetermined. OBJECTIVE: The main objective of this study was to critically assess current evidence with regard to the risk of development of ICH after the administration of intravenous tissue plasminogen activator for acute ischemic stroke in patients with CMBs. METHODS: The objective was addressed through the development of a critically appraised topic that included a clinical scenario, structured question, literature search strategy, critical appraisal, assessment of results, evidence summary, commentary, and bottom-line conclusions. Participants included consultant and resident neurologists, a medical librarian, clinical epidemiologists, and content experts in the field of vascular and hospital neurology. RESULTS: A recent individual patient data meta-analysis was selected for critical appraisal. Cohorts were analyzed with pretreatment magnetic resonance imaging to determine CMB burden and were followed-up to assess subsequent symptomatic ICH, hemorrhagic transformation, parenchymal hemorrhage (PH), and remote PH (PHr) following intravenous thrombolysis. Risk of symptomatic ICH, PH, and PHr was increased in the presence of CMBs, with PHr having the strongest association with increasing CMB burden. Only patients with >10 CMBs were found to have associations with poor outcome at 3 to 6 months, whereas there was no association with 3 to 6 months' mortality. CONCLUSIONS: CMBs are associated with an increased risk of postthrombolysis ICH; however, the clinical implications have yet to be determined.

Original languageEnglish (US)
Pages (from-to)40-43
Number of pages4
JournalThe neurologist
Volume24
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Cerebral Hemorrhage
Tissue Plasminogen Activator
Stroke
Hemorrhage
Intravenous Administration
Mobile Health Units
Librarians
Neurology
Consultants
Blood Vessels
Meta-Analysis
Magnetic Resonance Imaging
Mortality
Population

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Does High Cerebral Microbleed Burden Increase the Risk of Intracerebral Hemorrhage After Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke? / Arca, Karissa N.; Demaerschalk, Bart M; Almader-Douglas, Diana; Wingerchuk, Dean Marko; O'Carroll, Cumara B.

In: The neurologist, Vol. 24, No. 1, 01.01.2019, p. 40-43.

Research output: Contribution to journalArticle

@article{ba6c79c14a4847d0aa8837a73da94fbf,
title = "Does High Cerebral Microbleed Burden Increase the Risk of Intracerebral Hemorrhage After Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke?",
abstract = "BACKGROUND: The risk of developing intracerebral hemorrhage (ICH) after the administration of intravenous tissue plasminogen activator for acute ischemic stroke is well established in the general population. However, the risk associated with stroke thrombolysis in patients with a history of cerebral microbleeds (CMBs) is undetermined. OBJECTIVE: The main objective of this study was to critically assess current evidence with regard to the risk of development of ICH after the administration of intravenous tissue plasminogen activator for acute ischemic stroke in patients with CMBs. METHODS: The objective was addressed through the development of a critically appraised topic that included a clinical scenario, structured question, literature search strategy, critical appraisal, assessment of results, evidence summary, commentary, and bottom-line conclusions. Participants included consultant and resident neurologists, a medical librarian, clinical epidemiologists, and content experts in the field of vascular and hospital neurology. RESULTS: A recent individual patient data meta-analysis was selected for critical appraisal. Cohorts were analyzed with pretreatment magnetic resonance imaging to determine CMB burden and were followed-up to assess subsequent symptomatic ICH, hemorrhagic transformation, parenchymal hemorrhage (PH), and remote PH (PHr) following intravenous thrombolysis. Risk of symptomatic ICH, PH, and PHr was increased in the presence of CMBs, with PHr having the strongest association with increasing CMB burden. Only patients with >10 CMBs were found to have associations with poor outcome at 3 to 6 months, whereas there was no association with 3 to 6 months' mortality. CONCLUSIONS: CMBs are associated with an increased risk of postthrombolysis ICH; however, the clinical implications have yet to be determined.",
author = "Arca, {Karissa N.} and Demaerschalk, {Bart M} and Diana Almader-Douglas and Wingerchuk, {Dean Marko} and O'Carroll, {Cumara B.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1097/NRL.0000000000000228",
language = "English (US)",
volume = "24",
pages = "40--43",
journal = "Neurologist",
issn = "1074-7931",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Does High Cerebral Microbleed Burden Increase the Risk of Intracerebral Hemorrhage After Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke?

AU - Arca, Karissa N.

AU - Demaerschalk, Bart M

AU - Almader-Douglas, Diana

AU - Wingerchuk, Dean Marko

AU - O'Carroll, Cumara B.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - BACKGROUND: The risk of developing intracerebral hemorrhage (ICH) after the administration of intravenous tissue plasminogen activator for acute ischemic stroke is well established in the general population. However, the risk associated with stroke thrombolysis in patients with a history of cerebral microbleeds (CMBs) is undetermined. OBJECTIVE: The main objective of this study was to critically assess current evidence with regard to the risk of development of ICH after the administration of intravenous tissue plasminogen activator for acute ischemic stroke in patients with CMBs. METHODS: The objective was addressed through the development of a critically appraised topic that included a clinical scenario, structured question, literature search strategy, critical appraisal, assessment of results, evidence summary, commentary, and bottom-line conclusions. Participants included consultant and resident neurologists, a medical librarian, clinical epidemiologists, and content experts in the field of vascular and hospital neurology. RESULTS: A recent individual patient data meta-analysis was selected for critical appraisal. Cohorts were analyzed with pretreatment magnetic resonance imaging to determine CMB burden and were followed-up to assess subsequent symptomatic ICH, hemorrhagic transformation, parenchymal hemorrhage (PH), and remote PH (PHr) following intravenous thrombolysis. Risk of symptomatic ICH, PH, and PHr was increased in the presence of CMBs, with PHr having the strongest association with increasing CMB burden. Only patients with >10 CMBs were found to have associations with poor outcome at 3 to 6 months, whereas there was no association with 3 to 6 months' mortality. CONCLUSIONS: CMBs are associated with an increased risk of postthrombolysis ICH; however, the clinical implications have yet to be determined.

AB - BACKGROUND: The risk of developing intracerebral hemorrhage (ICH) after the administration of intravenous tissue plasminogen activator for acute ischemic stroke is well established in the general population. However, the risk associated with stroke thrombolysis in patients with a history of cerebral microbleeds (CMBs) is undetermined. OBJECTIVE: The main objective of this study was to critically assess current evidence with regard to the risk of development of ICH after the administration of intravenous tissue plasminogen activator for acute ischemic stroke in patients with CMBs. METHODS: The objective was addressed through the development of a critically appraised topic that included a clinical scenario, structured question, literature search strategy, critical appraisal, assessment of results, evidence summary, commentary, and bottom-line conclusions. Participants included consultant and resident neurologists, a medical librarian, clinical epidemiologists, and content experts in the field of vascular and hospital neurology. RESULTS: A recent individual patient data meta-analysis was selected for critical appraisal. Cohorts were analyzed with pretreatment magnetic resonance imaging to determine CMB burden and were followed-up to assess subsequent symptomatic ICH, hemorrhagic transformation, parenchymal hemorrhage (PH), and remote PH (PHr) following intravenous thrombolysis. Risk of symptomatic ICH, PH, and PHr was increased in the presence of CMBs, with PHr having the strongest association with increasing CMB burden. Only patients with >10 CMBs were found to have associations with poor outcome at 3 to 6 months, whereas there was no association with 3 to 6 months' mortality. CONCLUSIONS: CMBs are associated with an increased risk of postthrombolysis ICH; however, the clinical implications have yet to be determined.

UR - http://www.scopus.com/inward/record.url?scp=85059141197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059141197&partnerID=8YFLogxK

U2 - 10.1097/NRL.0000000000000228

DO - 10.1097/NRL.0000000000000228

M3 - Article

VL - 24

SP - 40

EP - 43

JO - Neurologist

JF - Neurologist

SN - 1074-7931

IS - 1

ER -